A Phase 3 interventional study of Ingavirin and Placebo oral capsule in Influenza, Human, Acute Respiratory Infection and Viral Infection, sponsored by Valenta Pharm JSC. Completed at 5 sites in Russian Federation. Open to participants aged 13 Years to 17 Years. Per ClinicalTrials.gov, last updated 2017-07-02.
Sponsored by Valenta Pharm JSC · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Influenza, Human by Valenta Pharm JSC — 4 open to participants now, 4 under way, none of them phase 3. Influenza, Human · Valenta Pharm JSC.
Among the 15 studies in Influenza, Human by Valenta Pharm JSC, this one is the 10th largest by enrollment, is the only one that started in 2012, is one of 7 in phase 3, and was the 5th registered.
2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.
Browse Influenza, Human studies →4 of the 15 studies in Influenza, Human by Valenta Pharm JSC are open now, in 2 countries. Recruiting first, the newest first:
Valenta Pharm JSC · Sites in Russia
Ages 18–65
Valenta Pharm JSC · Sites in Russia
Ages 18–45 · Healthy volunteers
Valenta Pharm JSC · Sites in Russia
Ages 18–45 · Healthy volunteers
Valenta Pharm JSC · Sites in Russian Federation
Ages 13–17
By country, each count listing its studies:
Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.
This study: 13 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2012.
This study's enrollment of 161 is below the median of 227 across 1,957 interventional studies indexed under Influenza, Human.
Median enrollment 240 across the 15 interventional studies. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Valenta Pharm JSC is the lead sponsor of 40 studies on the registry; 18 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Influenza, Human by Valenta Pharm JSC, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether Ingavirin ® dosed 60 mg daily is effective and safe in the treatment of influenza and other acute respiratory viral infections in 13-17 years old patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Broad spectrum antiviral drug
Drug: Ingavirin
Placebo capsule identical in appearance to Ingavirin capsule
Drug: Placebo oral capsule
Ingavirin ( Imidazolyl ethanamide pentandioic acid) capsules, 60 mg once daily, regardless of meal, for 5 days.
Also known as: Imidazolyl ethanamide pentandioic acid
Placebo, capsules daily for 5 days.
Time to resolution of fever
Time from the start of study treatment to resolution of fever ( t ≤ 36,9 ºС)
Time frame: 7 ± 1 days
Time to resolution of intoxication symptoms
Time from the start of study treatment to resolution of all intoxication symptoms.
Time frame: 7 ± 1 days
Time to resolution of catarrhal symptoms
Time from the start of study treatment to resolution of all catarrhal symptoms.
Time frame: 7 ± 1 days
Time to resolution/alleviation of cough
Time from the start of study treatment to resolution/alleviation of cough
Time frame: 7 ± 1 days
Proportion of subjects with development of complications of Influenza or other acute respiratory viral infection
Proportion of subjects who developed complications during treatment period (7 ± 1 days) and follow-up period (21 ± 1 days)
Time frame: 7 ± 1 days and 21 ± 1 days
Plan to share: No
Ran from Jan 2012 to primary completion in Nov 2012, 10 months.
Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's 10 months is above that.
Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pentanedioic acid imidazolyl ethanamide